L&T Technology Services Limited has announced a collaboration with NVIDIA to develop software-defined architectures for medical devices focused on endoscopy, which will enhance the image quality and scalability of products.
| Index | Prices | Change | Change% |
|---|---|---|---|
| Sensex | 65,690.67 | -104.06 | -0.16% |
| Nifty 50 | 19,717.50 | -14.30 | -0.07% |
| Nifty Bank | 43,472.50 | -111.45 | -0.26% |
| Biggest Gainer | Prices | Change | Change% |
|---|---|---|---|
| Divis Labs | 3,696.75 | 95.90 | +2.66% |
| Biggest Loser | Prices | Change | Change% |
|---|---|---|---|
| M&M | 1,567.40 | -17.15 | -1.08% |
| Best Sector | Prices | Change | Change% |
|---|---|---|---|
| Nifty IT | 32526.20 | 334.90 | +1.04% |
| Worst Sector | Prices | Change | Change% |
|---|---|---|---|
| Nifty Infra | 6411.60 | -18.00 | -0.28% |
L&T Technology Services Limited has announced a collaboration with NVIDIA to develop software-defined architectures for medical devices focused on endoscopy, which will enhance the image quality and scalability of products.
The High Court has passed a decree by recording the terms of the Settlement Agreement executed by the parties namely Exide Industries, Vertiv Company Group Limited UK (VCGL), and Vertiv Energy (VEPL), while disposing-off the suits pending since 2006. Both VCGL & VEPL agreed that they will not use the said CHLORIDE mark in India, either directly or indirectly, and will withdraw all their claims over this mark in favour of EXIDE. There is no financial impact on the company on account of above settlement of the suits, as EXIDE was anyway using the said CHLORIDE mark in India for its electronic products (UPS) during the litigation period since 2006.
| Company | CMP Chg(%) | Today Vol 5D Avg Vol | Vol Chg(%) |
|---|---|---|---|
| Prataap Snacks | 934.80 14.62% | 304.17k 20,746.80 | 1,366.00 |
| Summit Sec | 1,333.45 15.51% | 55.94k 7,950.00 | 604.00 |
| Lexus Granito | 45.45 15.21% | 49.92k 8,160.40 | 512.00 |
| DSPBANKETF | 43.81 -0.3% | 26.68k 5,385.60 | 395.00 |
| Hb Stockhol | 90.90 11.33% | 379.15k 78,238.40 | 385.00 |
| Talbros Auto | 278.25 18.53% | 887.83k 187,806.20 | 373.00 |
| Arabian Petrole | 83.80 11.58% | 194.00k 41,600.00 | 366.00 |
| Electrotherm | 158.85 4.99% | 4.59k 1,273.00 | 260.00 |
| EIH | 246.65 6.09% | 1.59m 464,650.00 | 242.00 |
| Skipper | 258.30 8.19% | 824.92k 253,639.80 | 225.00 |
| Company | Quantity | Price | Value(Cr) |
|---|---|---|---|
| Alok Industries | 328904 | 22.25 | 0.73 |
| Astra Microwave | 21224 | 566.75 | 1.2 |
| CAMS | 4435 | 2866 | 1.27 |
| Coal India | 33670 | 350.2 | 1.18 |
| IRFC | 250022 | 77.45 | 1.94 |
| ITI | 129338 | 281.25 | 3.64 |
| Jain Irrigation | 175264 | 71.05 | 1.25 |
| JK Bank | 183075 | 114 | 2.09 |
| JSW Energy | 35518 | 405.45 | 1.44 |
| JSW Energy | 25438 | 404.5 | 1.03 |
Tata Consultancy Services has fixed Saturday, November 25, 2023 as the record date for the purpose of determining the buyback entitlement and the names of the equity shareholders who will be eligible to participate in the Buyback.
The company to buyback up to 4,09,63,855 fully paid-up equity shares of face value of Rs 1 each at Rs 4,150 per equity share for an aggregate amount not exceeding RS 17,000 crore.
The United States Food and Drug Administration (US FDA) concluded a pre-approval inspection (PAI) at Unit-I & III, formulation manufacturing facility of APL Healthcare, in Telangana, with zero observations. The inspection, which was conducted during November 13-17 closed with a classification of No Action Indicated (NAI). APL Healthcare is a subsidiary of Aurobindo Pharma.
Cipla has received a Warning Letter dated 17th November, 2023 from United States Food and Drug Administration (USFDA) for the routine current Good Manufacturing Practices (cGMP) inspection conducted at its Pithampur manufacturing facility between 6th – 17th February, 2023.
This Warning Letter summarizes contraventions regarding methods or controls followed at the facility which do not conform to the prescribed cGMP regulations and contains directional guidance for necessary corrections
The pharma company has executed a Facility Demand Guarantee of ZAR 945 million in favour of First Rand Bank, South Africa, for extending general banking facilities to Medpro Pharmaceutica (Pty) Ltd. Medpro is a step down wholly owned subsidiary of Cipla in South Africa.
: Indian indices opened marginally lower on November 20 amid mixed gloabl cues.
The Sensex was down 18.49 points or 0.03 percent at 65,776.24, and the Nifty was up 0.60 points or 0.00 percent at 19,732.40. About 1809 shares advanced, 555 shares declined, and 182 shares unchanged.
Hindalco Industries, Apollo Hospitals, NTPC, Divis Labs and HCL Technologies were among major gainers on the Nifty, while losers were Axis Bank, Asian Paints, Kotak Mahindra Bank, Cipla and SBI Life Insurance.
The benchmark Sensex and Nifty indices are anticipated to open with a slight decline on November 20, as indications from the GIFT Nifty suggest a negative commencement for the broader index.
On November 17, both benchmarks concluded lower, with notable weakness observed in Bank Nifty, which closed 577 points lower at 43583.95, marking a crucial demand zone for the past seven months.
Nifty encountered resistance in the range of 19850-19900 and has struggled to break out from these levels for the past two months, indicating a robust supply zone at this level.
To facilitate an upward movement towards reclaiming levels of 20000-20200, NIFTY needs to surpass and sustain above 19850. Support is positioned at 19600-19400 levels.
Conversely, Bank Nifty has support at 43370-43000, with resistance at 44000-44420 that must be breached for further upside.
The selling activity by foreign institutional investors amounted to a net worth of Rs 477.76 crore, accompanied by domestic institutional investors offloading stocks worth Rs 565.48 crore on November 17, intensifying the downward pressure. It is advisable to adopt a stock-specific approach in today's trading session.
The markets settled the last day of the week on a tepid note at 19,731.80. We believe in the short run, the index will oscillate in a range where 19,850 will be a crucial resistance while the downside is protected at its strong support band of 19,550-19,580. In the case of BankNifty, the index is likely to retest its 200DMA support which comes around 43,250 while on the rise, it may face resistance at 44,060.
The much-awaited breakout was seen in the Auto and Infra sectors which indicates a continuation of an uptrend (Bajaj Auto, Eicher Motors, Hero Motocorp, Capacite Infraprojects, ITD Cementation, and Welspun Enterprises). An uptrend in the Pharma segment will continue from hereon as well as it has given a breakout from a Pennant and Pole formation (Dr Reddy, Zydus, and LifeGranules). We are bullish on the stocks that were previously mentioned as well i.e. Alkem, IPCA Labs, and Sun Pharma. Railway stocks are hinting towards another round of a rally (Ircon, IRFC, Railtel, TexRail, RVNL).
